Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials

Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials

AbstractBackground To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI).Methods Randomized controlled trials were searched from four Chinese and four English electronic databas...

Full description

Bibliographic Details
Main Authors: Fenglan Pu, Tianli Li, Chen Shen, Yingqiao Wang, Chunmei Tang, Xiaowen Zhang, Lijiao Yan, Qihe Xu, Jianping Liu
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Renal Failure
Subjects:
Chinese patent medicine
Ophiocordyceps sinensis
contrast-associated acute kidney injury
randomized clinical trials
systematic review
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2023.2300302

Internet

https://www.tandfonline.com/doi/10.1080/0886022X.2023.2300302

Similar Items